Q-omics provides the consensus-scored IL33 profile across patient tissues and cancer cell-line models. IL33 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, IL33 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, IL33 protein abundance shows 31,613 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, BLCA, and LSCC as cancer lineages where IL33 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IL33 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IL33 survival associations across molecular data types. IL33 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IL33 RNA expression–survival associations across cancer types. High IL33 expression shows unfavorable associations in KIRP, but favorable associations in BRCA, SKCM, LAML, COAD and LIHC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for IL33 RNA expression.
This table summarizes IL33 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 9. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for IL33. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IL33 shows lower tumor expression in BLCA, LUAD, THCA, HNSC, LUSC and LIHC. The BLCA box plot shows higher IL33 RNA expression in normal versus tumor tissue (log2 FC = −3.817, t-test p < 0.001).
This table shows molecular features associated with IL33 in patient tissues and cancer cell lines. In patient samples, IL33 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, IL33 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BREAST.
